Radovan Sašo
About
Radovan Sašo is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Radovan Sašo has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Hematology, 19 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Radovan Sašo's work include Multiple Myeloma Research and Treatments (20 papers), Hematopoietic Stem Cell Transplantation (18 papers) and Acute Myeloid Leukemia Research (12 papers). Radovan Sašo is often cited by papers focused on Multiple Myeloma Research and Treatments (20 papers), Hematopoietic Stem Cell Transplantation (18 papers) and Acute Myeloid Leukemia Research (12 papers). Radovan Sašo collaborates with scholars based in United Kingdom, United States and Australia. Radovan Sašo's co-authors include Seema Singhal, R Powles, Jayesh Mehta, C Horton, Bhawna Sirohi, S Kulkarni, J Treleaven, Gareth J. Morgan, Samar Kulkarni and Mark Ethell and has published in prestigious journals such as Blood, British Journal of Cancer and Journal of Theoretical Biology.
In The Last Decade
Radovan Sašo
49 papers receiving 1.2k citations
Peers
Radovan Sašo
Hirohito Yamazaki Japan
Attaphol Pawarode United States
Seung‐Ah Yahng South Korea
Ignacio Lorenzo Spain
Riccardo Centurioni Italy
M. J. Barnett Canada
Valérie Mialou France
Razvan Diaconescu United States
Satish Shanbhag United States
W.Y. Au China
Citations per year, relative to Radovan Sašo Radovan Sašo (= 1×)
peers
Hirohito Yamazaki
Countries citing papers authored by Radovan Sašo
Since
Specialization
Citations
This map shows the geographic impact of Radovan Sašo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radovan Sašo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radovan Sašo more than expected).
Fields of papers citing papers by Radovan Sašo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Radovan Sašo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radovan Sašo. The network helps show where Radovan Sašo may publish in the future.
Co-authorship network of co-authors of Radovan Sašo
This figure shows the co-authorship network connecting the top 25 collaborators of Radovan Sašo. A scholar is included among the top collaborators of Radovan Sašo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radovan Sašo. Radovan Sašo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bird, Sarah, Robyn Shea, Radovan Sašo, et al.. (2021). Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. The Lancet Haematology. 8(6). e389–e392.
2.
Koenders, M. A. & Radovan Sašo. (2015). A mathematical model of cell equilibrium and joint cell formation in multiple myeloma. Journal of Theoretical Biology. 390. 73–79.
3.
Hiwarkar, Prashant, Bronwen E. Shaw, J. Michael Tredger, et al.. (2010). Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. Clinical Transplantation. 25(2). 222–227.
4.
Sirohi, Bhawna, R Powles, Seema Singhal, et al.. (2008). Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. Leukemia & lymphoma. 49(12). 2284–2290.
5.
Davies, Faith E., Ping Wu, Matthew Jenner, et al.. (2008). Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT‐PACE. European Journal Of Haematology. 81(6). 432–436.
6.
Sirohi, Bhawna, R Powles, J Treleaven, et al.. (2008). The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplantation. 42(2). 105–112.
7.
Kulkarni, Shashikant, Radovan Sašo, Andrew Wotherspoon, et al.. (2008). High‐grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. British Journal of Haematology. 143(1). 71–74.
8.
Wu, Ping, Faith E. Davies, C Horton, et al.. (2006). The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leukemia & lymphoma. 47(11). 2335–2338.
9.
Alvares, Caroline, Faith E. Davies, C Horton, et al.. (2005). Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. British Journal of Haematology. 129(5). 607–614.
10.
Mehta, Jayesh, R Powles, Bhawna Sirohi, et al.. (2003). Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?. Bone Marrow Transplantation. 32(2). 157–164.
11.
Mehta, Jayesh, R Powles, Bhawna Sirohi, et al.. (2002). Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?. Bone Marrow Transplantation. 29(10). 853–859.
12.
Sirohi, Bhawna, R Powles, S Kulkarni, et al.. (2001). Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplantation. 28(1). 29–37.
13.
Singhal, Seema, R Powles, J Treleaven, et al.. (2000). A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold?. Bone Marrow Transplantation. 26(5). 489–496.
14.
Kulkarni, S, R Powles, J Treleaven, et al.. (2000). Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years. Bone Marrow Transplantation. 25(4). 365–370.
15.
Singhal, Seema, R Powles, S Kulkarni, et al.. (2000). Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. Bone Marrow Transplantation. 25(5). 501–505.
16.
Mehta, Jayesh, R Powles, Jennifer Treleaven, et al.. (1999). The Impact of Karyotype on Remission Rates in Adult Patients withde novoAcute Myeloid Leukemia Receiving High-Dose Cytarabine-Based Induction Chemotherapy. Leukemia & lymphoma. 34(5-6). 553–560.
17.
Sašo, Radovan, et al.. (1998). Secondary leukaemia characterised by monosomy 7 occurring post-autologous stem cell transplantation for AML. Bone Marrow Transplantation. 21(8). 853–855.
18.
Tooze, J. Adam, et al.. (1998). Deficiency of glycosylphosphatidyl inositol‐anchored proteins in patients with aplastic anaemia does not affect response to immunosuppressive therapy. British Journal of Haematology. 101(1). 90–93.
19.
Stojanović, Aleksandar, et al.. (1997). How Erythropoietin Affects Bone Marrow of Uremic Patients. American Journal of Nephrology. 17(2). 128–136.
20.
Sašo, Radovan, Athanasios Zomas, Michael R. Hamblin, et al.. (1997). Sequential Development of Myelodysplasia and Acute Myeloid Leukemia but with no Karyotypic Evolution after Autografting in a Patient with Philadelphia Positive Acute Lymphoblastic Leukemia. Leukemia & lymphoma. 26(5-6). 625–628.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hirohito Yamazaki Breakdown of academic impact, for papers by Attaphol Pawarode Breakdown of academic impact, for papers by Seung‐Ah Yahng Breakdown of academic impact, for papers by Ignacio Lorenzo Breakdown of academic impact, for papers by Riccardo Centurioni Breakdown of academic impact, for papers by M. J. Barnett Breakdown of academic impact, for papers by Valérie Mialou Breakdown of academic impact, for papers by Razvan Diaconescu Breakdown of academic impact, for papers by Satish Shanbhag Breakdown of academic impact, for papers by W.Y. Au